<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04821739</url>
  </required_header>
  <id_info>
    <org_study_id>AGN-CIP-200</org_study_id>
    <nct_id>NCT04821739</nct_id>
  </id_info>
  <brief_title>Study of the AGN1 LOEP SV Kit in Patients With Vertebral Compression Fractures</brief_title>
  <acronym>RISE</acronym>
  <official_title>A Prospective Multi-Center Study of the AGN1 Local Osteo-Enhancement Procedure (LOEP) SV Kit in Patients With Vertebral Compression Fractures (VCFs)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AgNovos Healthcare, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AgNovos Healthcare, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, single-arm, multi-center, European clinical study designed to&#xD;
      evaluate the clinical performance and safety of the AGN1 LOEP SV Kit for the treatment of&#xD;
      painful VCFs.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 19, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Back Pain from Baseline</measure>
    <time_frame>12 months</time_frame>
    <description>Change in Back Pain at 12 months from Baseline as indicated by Visual Analogue Scale (VAS), measured on a continuous 100 mm line.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Vertebral Compression Fracture</condition>
  <condition>Vertebral Compression</condition>
  <condition>Vertebral Fracture</condition>
  <arm_group>
    <arm_group_label>Treatment with AGN1 LOEP SV Kit</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VCF is treated with the AGN1 LOEP SV Kit</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AGN1 LOEP SV Kit</intervention_name>
    <description>The AGN1 LOEP SV Kit is intended for fixation of pathological fractures of the vertebral body using vertebral augmentation.</description>
    <arm_group_label>Treatment with AGN1 LOEP SV Kit</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is a male or female ≥ 55 years of age at time of treatment.&#xD;
&#xD;
          2. Subject is ≤ 85 years of age at time of treatment.&#xD;
&#xD;
          3. Subject has only one (1) VCF. Note the adjacent level vertebral bodies&#xD;
&#xD;
          4. This VCF meets all of the following criteria:&#xD;
&#xD;
               1. Fracture due to diagnosed or presumed underlying osteoporosis&#xD;
&#xD;
               2. VCF from T6 to L5 inclusive&#xD;
&#xD;
               3. Fracture age &lt; 3 months at time of treatment&#xD;
&#xD;
          5. Target VCF shows loss of height in the anterior or middle portion of the vertebral&#xD;
             body of not more than 40% based on X-ray at baseline.&#xD;
&#xD;
          6. Target VCF is acute or persistent (not healed), as demonstrated by T2 weighted STIR&#xD;
             MRI or bone scan imaging.&#xD;
&#xD;
          7. Subject has central pain upon palpation over the spinal process at the target&#xD;
             vertebral body.&#xD;
&#xD;
          8. Subject has failed conservative medical therapy, defined as either having a VAS back&#xD;
             pain score of ≥ 70 mm after 2 to 6 weeks of conservative care or a VAS back pain score&#xD;
             of ≥ 50 mm after 6 weeks of conservative care.&#xD;
&#xD;
          9. Subject has an Oswestry Disability Index (ODI) score of ≥ 30%.&#xD;
&#xD;
         10. Subject is capable of giving written informed consent to participate in the study.&#xD;
&#xD;
         11. The subject's willingness, ability, and commitment to participate in screening,&#xD;
             treatment, and all follow-up evaluations for the full length of the study has been&#xD;
             documented.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Target VCF is due to underlying or suspected tumor.&#xD;
&#xD;
          2. Target VCF is due to high-energy trauma.&#xD;
&#xD;
          3. Target VCF is diagnosed as an osteonecrotic fracture.&#xD;
&#xD;
          4. Target VCF has segmental kyphosis of &gt; 30°.&#xD;
&#xD;
          5. Target VCF is unstable including split or burst fractures.&#xD;
&#xD;
          6. Subject has had any prior surgical treatment at the target VCF or adjacent vertebral&#xD;
             level (above or below VCF).&#xD;
&#xD;
          7. Subject has neurologic symptoms, deficits, or radiculopathy related to the VCF.&#xD;
&#xD;
          8. Subject has spinal canal compromise causing clinical manifestations of cord, neural&#xD;
             foramen, or nerve root compression at the level to be treated.&#xD;
&#xD;
          9. Subject has pain based on clinical diagnosis of herniated nucleus pulposus or severe&#xD;
             spinal stenosis (progressive weakness or paralysis).&#xD;
&#xD;
         10. Subject has spondylolisthesis &gt; Grade 1 at target vertebral body.&#xD;
&#xD;
         11. Subject has pain due to any other condition that requires daily narcotic medication.&#xD;
&#xD;
         12. Subject has severe cardiopulmonary deficiencies.&#xD;
&#xD;
         13. Subject has a bleeding disorder.&#xD;
&#xD;
         14. Subject has a Body Mass Index (BMI) &gt; 35.&#xD;
&#xD;
         15. Subject has a history of metabolic bone disease other than osteoporosis (e.g., Paget's&#xD;
             disease, renal osteodystrophy, or osteomalacia).&#xD;
&#xD;
         16. Subject has a history of tuberculosis spondylitis.&#xD;
&#xD;
         17. Subject has a history of any invasive malignancy (except non-melanoma skin cancer),&#xD;
             unless treated with curative intent and with no clinical signs or symptoms of the&#xD;
             malignancy for five (5) years.&#xD;
&#xD;
         18. Subject is on oral or parenteral immune-suppressive drugs.&#xD;
&#xD;
         19. Subject has an active bone infection at target VCF.&#xD;
&#xD;
         20. Subject has uncontrolled diabetes mellitus, as determined by the judgment of the&#xD;
             Investigator.&#xD;
&#xD;
         21. Subject has severe renal insufficiency defined as an estimated glomerular filtration&#xD;
             rate (eGFR) &lt; 30 mL/min.&#xD;
&#xD;
         22. Subject has albumin corrected serum calcium levels outside the normal lab range or has&#xD;
             a pre-existing calcium metabolism disorder (e.g., hypercalcemia).&#xD;
&#xD;
         23. Subject has known allergies to calcium-based bone void fillers.&#xD;
&#xD;
         24. Subject is pregnant or planning to become pregnant during participation in the study.&#xD;
&#xD;
         25. In the judgment of the Investigator, the subject is not a good study candidate (e.g.,&#xD;
             inability to maintain follow-up schedule, comorbidity or poor general physical/mental&#xD;
             health, or drug or alcohol abuse issues).&#xD;
&#xD;
         26. Subject is currently enrolled in another interventional clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacques Müller- Broich</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orthopaedic University Hospital Friedrichsheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adam Lowe</last_name>
    <phone>240-753-6416</phone>
    <email>alowe@agnovos.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mike Anibaba</last_name>
    <phone>240-753-6427</phone>
    <email>manibaba@aganovos.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Orthopedic University Hospital Friedrichsheim</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60528</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antje Steidl</last_name>
    </contact>
    <investigator>
      <last_name>Jacques Müller- Broich</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>March 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2021</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Spinal Fractures</mesh_term>
    <mesh_term>Fractures, Compression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

